NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
Treatment of COPD: Stepwise Approach to Treatment and Attempts to Alter the Natural History of the Disease
1.00 AMA PRA Category 1 Credits
Incorporate COPD drug therapy in a stepwise approach, and discuss recent attempts to alter the natural course of COPD in order to improve patient outcomes with respect to premature death and progressive loss of lung function.
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.
||AMA PRA Category 1 Credits
||pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
||pmiCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty and Editorial Board
Stephen P. Peters, MD, PhD, Professor of Genomics and Personalized Medicine Research, Internal Medicine & Pediatrics, Associate Director, Center for Genomics and Personalized Medicine Research, Wake Forest University Health Sciences Center for Genomics and Personalized Medicine Research, Winston-Salem, North Carolina
Carolyn Skowronski, PharmD, pmiCME
Financial Disclosure Statement(s)
Dr Peters discloses that he receives consulting fees from Aerocrine, AstraZeneca, Genentech/Novartis, Johnson & Johnson, Merck & Co., Sepracor, TEVA, Abbott Laboratories, and AsthmaTx, and research funding from Abaris, Altana, Boerhinger Ingelheim, Centocor, Genentech, GlaxoSmithKline, Medimmune, Pfizer, Schering, Wyeth, the American Lung Association, and the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network.
Ms Skowronski discloses she holds stock in Merck.
Nizar N. Jarjour, MD, Educational Content Reviewer, discloses that he has consulting relationships with Asthmatx and Genentech-Novartis, and research funding from GlaxoSmithKline, Merck & Co., and MedImmune.
Steven Folstein, Director of Education, American Academy of Allergy, Asthma and Immunology, has no financial relationships to disclose.
pmiCME along with the American Academy of Allergy, Asthma & Immunology (AAAAI) are part of the ACES (Asthma and COPD Education Solutions) Consortium. This national CME initiative is a coordinated effort to improve the standards of care for patients with non-contagious chronic respiratory conditions. Funding for this initiative is obtained from multiple sources including commercial support. Receipt of these funds is project based and acknowledged by the partner organizations that are responsible for those identified projects.
pmiCME and AAAAI receive funding from GlaxoSmithKline in support of this educational activity, which is part of the ACES Consortium initiative.
American Academy of Allergy, Asthma & Immunology
pmiCME and AAAAI, through the University of North Texas Health Science Center at Fort Worth, received funding from GlaxoSmithKline in support of this educational activity, which is part of the ACES Consortium initiative.
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.